Pages that link to "Q40682505"
Jump to navigation
Jump to search
The following pages link to Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate (Q40682505):
Displaying 18 items.
- Estramustine Phosphate Sodium (Q29391791) (← links)
- Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial (Q32040849) (← links)
- The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group (Q33348552) (← links)
- Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma (Q33349098) (← links)
- Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer (Q33366110) (← links)
- Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma (Q33653596) (← links)
- Chemotherapy for hormone refractory prostate cancer. (Q33653616) (← links)
- Hormone refractory prostate cancer (Q33800958) (← links)
- Chemotherapy for advanced hormone refractory prostate cancer (Q33800983) (← links)
- Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? (Q34155429) (← links)
- Paclitaxel and docetaxel in prostate cancer (Q34348284) (← links)
- Treatment options in hormone-refractory prostate cancer: current and future approaches (Q34481266) (← links)
- The treatment of prostate cancer: an overview of current options (Q34552438) (← links)
- Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (Q36673680) (← links)
- A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate (Q37119421) (← links)
- A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer (Q46495105) (← links)
- Current clinical trial design issues in hormone-refractory prostate carcinoma (Q48017947) (← links)
- A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer (Q51055415) (← links)